10x Genomics (MEX:TXG) Change In Receivables : MXN785 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is 10x Genomics Change In Receivables?

10x Genomics's change in receivables for the quarter that ended in Mar. 2025 was MXN723 Mil. It means 10x Genomics's Accounts Receivable declined by MXN723 Mil from Dec. 2024 to Mar. 2025 .

10x Genomics's change in receivables for the fiscal year that ended in Dec. 2024 was MXN562 Mil. It means 10x Genomics's Accounts Receivable declined by MXN562 Mil from Dec. 2023 to Dec. 2024 .

10x Genomics's Accounts Receivable for the quarter that ended in Mar. 2025 was MXN1,075 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. 10x Genomics's Days Sales Outstanding for the three months ended in Mar. 2025 was 30.96.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. 10x Genomics's liquidation value for the three months ended in Mar. 2025 was MXN6,284 Mil.

10x Genomics Change In Receivables Historical Data

The historical data trend for 10x Genomics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Change In Receivables Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-355.01

-698.32

-369.41

-180.15

562.08

10x Genomics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															390.28	2.24	151.28	-91.14	722.69

10x Genomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN785 Mil.

10x Genomics (MEX:TXG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

10x Genomics's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1075.058	/	3168.627	*	91
=	30.96

2. In Ben Graham's calculation of liquidation value, 10x Genomics's accounts receivable are only considered to be worth 75% of book value:

10x Genomics's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8733.708	-	4019.995	+	0.75 * 1075.058	+	0.5 * 1528.432
=	6,284

10x Genomics Change In Receivables Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (MEX:TXG) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

TXG:USA 0A88:UK 1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).